Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) Latest Company News

Oct 29, 2026, 10:36 UTC
Changchun High-Tech reported revenue of 8.251 billion yuan for the first three quarters of 2026, down 15.86% year over year, and net profit attributable to shareholders of 586 million yuan, down 49.68%.
Source:
- finance.sina.cn
Oct 29, 2026, 10:36 UTC
Changchun High-Tech reported third-quarter 2026 revenue of 2.708 billion yuan, down 15.46% year over year, and net profit attributable to shareholders of 111 million yuan, down 39.12%.
Source:
- finance.sina.cn
Oct 20, 2026, 10:08 UTC
China's National Medical Products Administration accepted clinical trial registration applications for Jinsai Pharmaceutical's GenSci155 injection, developed for intracerebral hemorrhage treatment.
Source:
- finance.sina.cn
Oct 13, 2026, 10:58 UTC
China's National Medical Products Administration accepted GenSci161 injection's clinical-trial application for domestic production, as announced by Changchun High-Tech on October 13.
Source:
- finance.sina.cn
Oct 8, 2026, 11:19 UTC
China's National Medical Products Administration approved Jinsai Pharmaceutical's application to register and market a 42 mg leuprorelin mesylate injection for prostate cancer requiring androgen-deprivation therapy.
Source:
- finance.sina.cn
- finance.sina.cn
Oct 7, 2026, 07:34 UTC
China's National Medical Products Administration approved GenSci155 injection for clinical trials in China, for prevention of bronchopulmonary dysplasia in premature infants and treatment of primary insulin-like growth factor-1 deficiency.
Source:
- finance.sina.cn
Aug 31, 2026, 11:29 UTC
Changchun High-tech's subsidiary Jinsai Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of GenSci161 injection, a self-developed biologic drug for connective tissue disease-associated interstitial lung disease.
Source:
- finance.sina.cn
Aug 20, 2026, 08:55 UTC
Changchun High-Tech announced it will not distribute cash dividends, bonus shares, or convert capital reserve to share capital for H1 2026.
Source:
- finance.sina.cn
Aug 20, 2026, 08:55 UTC
Changchun High-Tech announced its H1 2026 results: revenue of 5.543 billion yuan, down 16.06% year-on-year; net profit attributable to shareholders of 475 million yuan, down 51.64% year-on-year; non-GAAP net profit of 496 million yuan, down 52.02% year-on-year.
Source:
- finance.sina.cn
Aug 10, 2026, 10:53 UTC
Changchun High-tech subsidiary Jinsai Pharmaceutical's GenSci148 injection clinical trial application for domestic production was approved by the National Medical Products Administration, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Source:
- finance.sina.cn
Aug 5, 2026, 08:41 UTC
Changchun High-Tech's controlling subsidiary Jinsai Pharmaceutical received an acceptance notice from the National Medical Products Administration for the clinical trial application of its self-developed GenSci133 injection, a PTH polypeptide and anti-RANKL antibody fusion protein intended for the treatment of osteoporosis.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 30, 2026, 08:34 UTC
GenSci144 tablet obtained approval from China's National Medical Products Administration to conduct a domestic production drug registration clinical trial for chronic kidney disease.
Source:
- finance.sina.cn
Jul 24, 2026, 10:18 UTC
Changchun High-Tech subsidiary Jinsai Pharmaceutical's clinical trial application for subcutaneous administration of GenSci155 injection for prevention of bronchopulmonary dysplasia in preterm infants has been accepted by China's National Medical Products Administration.
Source:
- finance.sina.cn
Jul 21, 2026, 09:06 UTC
Changchun High-Tech's subsidiary Changchun Jinsai Pharmaceutical's Gentuximab injection marketing application was accepted by the National Medical Products Administration.
Source:
- finance.sina.cn
Jul 3, 2026, 11:06 UTC
Changchun High-Tech's subsidiary Jinsai Pharmaceutical received approval from the National Medical Products Administration for the clinical trial application of its self-developed GenSci164 injection for treating hypoparathyroidism.
Source:
- finance.sina.cn

000661.SZ

Changchun High-Tech reported revenue of 8.251 billion yuan for the first three quarters of 2026, down 15.86% year over year, and net profit attributable to shareholders of 586 million yuan, down 49.68%.

Changchun High-Tech reported third-quarter 2026 revenue of 2.708 billion yuan, down 15.46% year over year, and net profit attributable to shareholders of 111 million yuan, down 39.12%.

China's National Medical Products Administration accepted clinical trial registration applications for Jinsai Pharmaceutical's GenSci155 injection, developed for intracerebral hemorrhage treatment.

China's National Medical Products Administration accepted GenSci161 injection's clinical-trial application for domestic production, as announced by Changchun High-Tech on October 13.

China's National Medical Products Administration approved Jinsai Pharmaceutical's application to register and market a 42 mg leuprorelin mesylate injection for prostate cancer requiring androgen-deprivation therapy.

China's National Medical Products Administration approved GenSci155 injection for clinical trials in China, for prevention of bronchopulmonary dysplasia in premature infants and treatment of primary insulin-like growth factor-1 deficiency.

Changchun High-tech's subsidiary Jinsai Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of GenSci161 injection, a self-developed biologic drug for connective tissue disease-associated interstitial lung disease.

Changchun High-Tech announced it will not distribute cash dividends, bonus shares, or convert capital reserve to share capital for H1 2026.

Changchun High-Tech announced its H1 2026 results: revenue of 5.543 billion yuan, down 16.06% year-on-year; net profit attributable to shareholders of 475 million yuan, down 51.64% year-on-year; non-GAAP net profit of 496 million yuan, down 52.02% year-on-year.

GenSci144 tablet obtained approval from China's National Medical Products Administration to conduct a domestic production drug registration clinical trial for chronic kidney disease.

Changchun High-Tech subsidiary Jinsai Pharmaceutical's clinical trial application for subcutaneous administration of GenSci155 injection for prevention of bronchopulmonary dysplasia in preterm infants has been accepted by China's National Medical Products Administration.

Changchun High-Tech's subsidiary Changchun Jinsai Pharmaceutical's Gentuximab injection marketing application was accepted by the National Medical Products Administration.

Changchun High-Tech's subsidiary Jinsai Pharmaceutical received approval from the National Medical Products Administration for the clinical trial application of its self-developed GenSci164 injection for treating hypoparathyroidism.